V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Amicus Therapeutics Executive Compensation (FY24)

FOLD · Executive and director compensation, fiscal 2022 to 2024
Data as of September 7, 2026Latest filing (8-K): June 5, 2025
433 figures on this page: 425 cited to the filing that reported them, 8 calculated from figures it prints. See the citations
Bradley Campbell, President and Chief Executive Officer, received $8,526,943 in total compensation for fiscal 2024, and Campbell's total was 4.0% higher than the $8,202,366 reported for fiscal 2023. For fiscal 2024, the company reported a chief executive pay ratio of 33:1, against median employee compensation of $259,999. For fiscal 2024, shareholders backed the say-on-pay proposal with 97.4% of votes cast including abstentions in favor at the meeting held June 5, 2025. The disclosed peer group includes Acadia Pharmaceuticals, Agios Pharmaceuticals, Alkermes, Apellis Pharmaceuticals and Axsome Therapeutics, Inc., among others.
Chief executive, fiscal 2024
◇
Bradley Campbell
Latest say-on-pay support
=
June 5, 2025
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Bradley Campbell: $8,202,366 → $8,526,943 (4.0% higher)
Say-on-pay support: 96.7% → 97.4% (0.7 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Amicus Therapeutics' chief executive and what were they paid?
Bradley Campbell, President and Chief Executive Officer, received $8,526,943 in total compensation for fiscal 2024. Campbell's total was 4.0% higher than the $8,202,366 reported for fiscal 2023.
What was Amicus Therapeutics' say-on-pay result?
For fiscal 2024, shareholders backed the say-on-pay proposal with 97.4% of votes cast including abstentions in favor at the meeting held June 5, 2025.
Which companies are in Amicus Therapeutics' peer group?
The disclosed peer group includes Acadia Pharmaceuticals, Agios Pharmaceuticals, Alkermes, Apellis Pharmaceuticals and Axsome Therapeutics, Inc., among others.
What is Amicus Therapeutics' chief executive pay ratio?
For fiscal 2024, the company reported a chief executive pay ratio of 33:1, against median employee compensation of $259,999.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bradley Campbell
President and Chief Executive Officer
◇◇◇◇——◇◇
Ellen Rosenberg
Chief Legal Officer and Corporate Secretary
◇◇◇◇—◇◇◇
Jeffrey Castelli
Chief Development Officer
◇◇◇◇——◇◇
David Clark
Chief People Officer
◇◇◇◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bradley Campbell
President and Chief Executive Officer
◇◇◇◇——◇◇
Ellen Rosenberg
Chief Legal Officer and Corporate Secretary
◇◇◇◇—◇◇◇
Jeffrey Castelli
Chief Development Officer
◇◇◇◇——◇◇
David Clark
Chief People Officer
◇◇◇◇——◇◇
Simon Harford
Chief Financial Officer
◇◇◇◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bradley Campbell
President and Chief Executive Officer
◇◇◇◇——◇◇
Ellen Rosenberg
Chief Legal Officer and Corporate Secretary
◇◇◇◇——◇◇
Simon Harford
Chief Financial Officer
◇◇◇◇——◇◇
Jeffrey Castelli
Chief Development Officer
◇◇◇◇——◇◇
David Clark
Chief People Officer
◇◇◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Bradley L. CampbellPSU◇◇◇—◇—◇
Bradley L. CampbellPSU◇◇◇—◇—◇
Bradley L. CampbellPSU◇◇◇—◇—◇
Bradley L. CampbellRSU◇——◇——◇
Bradley L. CampbellOPTION◇——◇—◇◇
David M. ClarkPSU◇◇◇—◇—◇
David M. ClarkPSU◇◇◇—◇—◇
David M. ClarkPSU◇◇◇—◇—◇
David M. ClarkOPTION◇——◇—◇◇
David M. ClarkRSU◇——◇——◇
Ellen RosenbergPSU◇◇◇—◇—◇
Ellen RosenbergRSU◇——◇——◇
Ellen RosenbergPSU◇◇◇—◇—◇
Ellen RosenbergPSU◇◇◇—◇—◇
Ellen RosenbergOPTION◇——◇—◇◇
Jeffrey P. CastelliRSU◇——◇——◇
Jeffrey P. CastelliPSU◇◇◇—◇—◇
Jeffrey P. CastelliPSU◇◇◇—◇—◇
Jeffrey P. CastelliPSU◇◇◇—◇—◇
Jeffrey P. CastelliOPTION◇——◇—◇◇
Simon HarfordOPTION◇——◇—◇◇
Simon HarfordRSU◇——◇——◇
Simon HarfordPSU◇◇◇—◇—◇
Simon HarfordPSU◇◇◇—◇—◇
Simon HarfordPSU◇◇◇—◇—◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Bradley CampbellOption◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
Simon HarfordRSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇—
David ClarkRSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
Jeffrey CastelliRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
Ellen RosenbergOption◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John F. Crowley
—◇◇——◇◇
Michael G. Raab
Board chair
◇◇◇———◇
Glenn P. Sblendorio
◇◇◇———◇
Margaret G. McGlynn
◇◇◇———◇
Craig A. Wheeler
◇◇◇———◇
Lynn D. Bleil
◇◇◇———◇
Michael A. Kelly
◇◇◇———◇
Burke W. Whitman
◇◇◇———◇
Eiry W. Roberts
◇◇◇———◇
Bradley L. Campbell served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • Acadia Pharmaceuticals ACAD
  • Agios Pharmaceuticals AGIO
  • Alkermes ALKS
  • Apellis Pharmaceuticals APLS
  • Axsome Therapeutics, Inc. AXSM
  • Blueprint Medicines Corporation BPMC
  • Catalyst Pharmaceuticals, Inc. CPRX
  • Exelixis EXEL
  • Halozyme Therapeutics HALO
  • Harmony Biosciences HRMY
  • Ionis Pharmaceuticals IONS
  • Ironwood Pharmaceuticals IRWD
  • Mirum Pharmaceuticals, Inc. MIRM
  • PTC Therapeutics PTCT
  • Travere Therapeutics TVTX
  • Ultragenyx Pharmaceuticals RARE

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024June 5, 2025=◇◇◇
2023June 6, 2024=◇◇◇
2022June 8, 2023=◇◇◇
2021June 9, 2022=◇◇◇
2020June 10, 2021=◇◇◇
2019June 4, 2020=◇◇◇
2018June 27, 2019=◇◇◇
2017June 8, 2018=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Amicus Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Amicus Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Amicus Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Amicus Therapeutics' disclosed peer group is defensible, who names Amicus Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
433 figures on this page: 425 cited to the filing that reported them, 8 calculated from figures it prints.
425 cited to the filing
8 calculated from the filing

Documents cited

  1. 0001104659-25-056821
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001140361-25-015479
    CEO Pay Ratio · Director Compensation Table · Grants of Plan-Based Awards · Outstanding Equity Awards at Fiscal Year End · and 2 more sections
  3. 0001104659-24-069634
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001140361-24-021745
    Summary Compensation Table
  5. 0001104659-23-070827
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001140361-23-020594
    Summary Compensation Table
  7. 0001104659-22-070104
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001104659-21-080496
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001178879-20-000025
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001178879-19-000054
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001104659-18-039068
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Amicus Therapeutics executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/FOLD (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Amicus Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Amicus Therapeutics discloses

The companies named in FOLD's own disclosed peer group.

Acadia PharmaceuticalsAgios PharmaceuticalsAlkermesApellis PharmaceuticalsExelixisHalozyme TherapeuticsIonis PharmaceuticalsIronwood PharmaceuticalsMirum Pharmaceuticals, Inc.PTC TherapeuticsTravere TherapeuticsUltragenyx Pharmaceuticals

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy